Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
about
Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort studyKlotho in cardiovascular disease: Current and future perspectivesRegulation and function of the FGF23/klotho endocrine pathwaysKlotho and phosphate are modulators of pathologic uremic cardiac remodeling.Calcium and phosphate impact cardiovascular risk.Fibroblast Growth Factor-23-A Potential Uremic ToxinBone and muscle: Interactions beyond mechanical.Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolismHigher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patientsFibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS)FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.The use of fibroblast growth factor 23 testing in patients with kidney disease.The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney diseaseThe phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.FGF23 induces left ventricular hypertrophyFGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.Fibroblast growth factor-23 and cardiac structure and function.Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis.FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure.Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of AtherosclerosisFibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseTertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrationsArterial klotho expression and FGF23 effects on vascular calcification and function.Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyLeft ventricular hypertrophy and chronic renal insufficiency in the elderly.Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatientsFibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trialFibroblast growth factor 23 and risk of incident stroke in community-living adultsFibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients.Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion.Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney diseaseAssociations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adultsTreatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
P2860
Q22306543-DB5A3289-D1DD-4BDD-8289-4123E1C3E596Q26775409-5F67310F-EAB6-462D-96D7-74A54DD7618AQ26860470-818120CA-599D-4AC7-AF80-8324AEF09023Q27342649-6A3714D6-B789-4023-AED7-528E7FFF925DQ27687570-77A3604F-8824-4DD1-81CB-88E613374EF1Q28075648-D1A42567-3BBA-4815-B84C-3C6A8D34B40DQ28606563-5BAA8B6E-BD83-4DCD-9EA6-778D0B8F7438Q30427104-AFDEB5DB-855A-42A0-9C12-86D74E3CED9BQ30544587-088E9641-0F98-4C3B-92E1-6790FB0AE9C2Q33600110-1E14C0B1-3392-41CF-918C-147E05129053Q33650866-2F43AE9F-7D99-45F3-88A4-155D3D46AFEDQ33654616-BB7B12F2-C1C1-41B1-BE8A-B8F094170543Q33694566-E6EE15FA-BE6E-4EAA-A1F5-EEF1D69FD03FQ33835743-7BDD42A9-F847-45DF-B370-988C56BC566CQ34022484-CDA4AE2A-AE4B-458F-AAB1-80452FFE33A1Q34027316-DA4CC96F-B8FF-4531-8133-F8CECFDD71ECQ34027561-F9B55A7E-F02F-465B-AF12-C4741839F529Q34028891-B91BC891-EAD2-426D-AF5E-893C2959FC1FQ34035797-3A8689B1-B8F6-4330-B356-E0BD3FCED9C9Q34039877-B0FD486A-0EA6-4C7A-96C5-EC9703E335F2Q34069793-54B738BC-8463-4BE7-9C21-6187843C7003Q34130840-632CE0AD-EFF0-41BE-9E81-3E7D15F75A54Q34255342-7C66718E-8E7B-4463-AAED-74B9F5CCB7C8Q34406871-BD3F2DA5-14EA-4C42-B9C5-815604458709Q34421217-2C714F91-EC0B-404A-BA2D-AF9EB54F8355Q34500628-C76C6620-C212-42DF-9398-775947BADC2FQ34650666-71B3429F-5442-4493-99EC-8A4A2FA59143Q34663898-92DAF366-E3EF-4110-BCCD-7838EE30F309Q34669005-FFE98A8C-27D1-4136-8338-B688E6C2B724Q34739121-D7BE79A6-E63F-4B75-9D99-3F50652B985BQ34985754-FF62AA09-18D2-4A63-A15C-1C39180EFA62Q34988878-7123B0C9-011F-4718-87E3-5700D984B6A5Q35008805-BEB1DC9B-A090-42D8-B5F4-66357DE4551CQ35019943-D72AE70F-97EB-43FC-B213-5FD85C78AE6FQ35021985-CB25336F-98DF-4ADC-AD18-155029E68F66Q35026687-BBE5B9E8-6AC1-433A-8217-943BA8FD2FD8Q35069203-690FEA13-F23A-4609-8DAC-BC2F8FBB3A42Q35210184-9A0DB7CF-6A8F-4A22-8836-15736128DD29Q35220170-382ECC86-BC09-42EB-BB32-C08FAAB20BB1Q35588217-AE78A00C-61CB-4E0A-9C3C-54738D4EEB10
P2860
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Serum intact FGF23 associate w ...... etry in an elderly population.
@ast
Serum intact FGF23 associate w ...... etry in an elderly population.
@en
Serum intact FGF23 associate w ...... etry in an elderly population.
@nl
type
label
Serum intact FGF23 associate w ...... etry in an elderly population.
@ast
Serum intact FGF23 associate w ...... etry in an elderly population.
@en
Serum intact FGF23 associate w ...... etry in an elderly population.
@nl
prefLabel
Serum intact FGF23 associate w ...... etry in an elderly population.
@ast
Serum intact FGF23 associate w ...... etry in an elderly population.
@en
Serum intact FGF23 associate w ...... etry in an elderly population.
@nl
P2093
P1433
P1476
Serum intact FGF23 associate w ...... etry in an elderly population.
@en
P2093
Håkan Melhus
Majd A I Mirza
Tobias E Larsson
P304
P356
10.1016/J.ATHEROSCLEROSIS.2009.05.013
P577
2009-05-21T00:00:00Z